Getting to the Heart of ATTR-CM: Assessment, Trials, and Treatment Strategies

Meeting Objectives:

• • Review the pathophysiology, clinical presentation, and diagnostic biomarkers of transthyretin amyloid cardiomyopathy (ATTR-CM) to support early recognition and accurate staging in clinical practice. 
  • Examine key findings from pivotal Phase 3 clinical trials of approved ATTR-CM therapies, including differences in patient populations, genotype variations, NYHA classification, and clinical outcomes. 
  • Compare current treatment options for ATTR-CM based on mechanisms of action, pharmacokinetics, safety profiles, shared decision-making, and other practical considerations to guide therapy selection across diverse patient populations.